Literature DB >> 25054006

Promoter region methylation and loss of protein expression of PTEN and significance in cervical cancer.

Qiufeng Qi1, Yang Ling2, Ming Zhu1, Linyan Zhou3, Meizhen Wan3, Yanqing Bao1, Yongping Liu4.   

Abstract

The genetic basis underlying cervical tumorigenesis and progression are largely unknown. Phosphatase and tensin homologue (PTEN) is a tumor suppressor gene, and genetic changes of PTEN occurs in various types of cancer suggesting that the inactivation of PTEN may play an important role in the pathogenesis of a variety of human malignancies. In the present study, 102 cervical cancer specimens were examined for the expression of the PTEN gene and promoter methylation using methylation-specific-polymerase chain reaction and immunohistochemistry. The PTEN gene mutation was also assessed using PCR single-strand conformational polymorphism. We examined the correlation between PTEN expression and its associated methylation status and the clinical characteristics of cervical cancer. The results showed that there was one case of an A to G point mutation on exon 9 of the PTEN gene in the cervical cancer tissues. This mutation caused the change of aspartic acid to glycine, and the rate of mutation was 1%. The PTEN gene methylation rate of cervical cancer was 62% (63/102) and the rate was associated with the International Federation of Gynecology and Obstetrics stage, cell differentiation, tumor size and lymph node metastasis (P<0.05). The positive rate of PTEN expression was 49% (50/102) in cervical carcinoma and the PTEN expression between stage I-II and III-IV [60 (27/45) vs. 40% (23/57)] was statistically significant (P<0.01). The PTEN gene expression between the metastasis and no lymph node metastasis groups [26 (10/38) vs. 63% (40/64)] was significantly different (P<0.01). The PTEN gene promoter methylation and its protein expression had a significant correlation (P=0.042). These results suggest that hypermethylation can inactivate the transcription of PTEN and reduce its protein expression. Downregulated PTEN expression is involved in the pathogenesis, invasion and metastasis of cervical cancer, possibly by regulating the balance between apoptosis and proliferation. Therefore, the PTEN expression may be a good marker for the prognosis of cervical cancer.

Entities:  

Keywords:  cervical cancer; immunohistochemistry; methylation; mutation; phosphatase and tensin homologue gene

Year:  2014        PMID: 25054006      PMCID: PMC4106585          DOI: 10.3892/br.2014.298

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  28 in total

1.  Abnormal structure and expression of PTEN/MMAC1 gene in human uterine cancers.

Authors:  Y Yaginuma; T Yamashita; T Ishiya; A Morizaki; Y Katoh; T Takahashi; H Hayashi; M Ishikawa
Journal:  Mol Carcinog       Date:  2000-02       Impact factor: 4.784

2.  Hypermethylation of the PTEN gene in ovarian cancer cell lines.

Authors:  Thomas Schöndorf; Matthias P Ebert; Juliane Hoffmann; Martina Becker; Natasha Moser; Saziye Pur; Uwe-Jochen Göhring; Maria-Paz Weisshaar
Journal:  Cancer Lett       Date:  2004-04-30       Impact factor: 8.679

3.  Regulation of cell migration by the C2 domain of the tumor suppressor PTEN.

Authors:  Myrto Raftopoulou; Sandrine Etienne-Manneville; Annette Self; Sarah Nicholls; Alan Hall
Journal:  Science       Date:  2004-02-20       Impact factor: 47.728

4.  PCR-SSCP-DNA sequencing method in detecting PTEN gene mutation and its significance in human gastric cancer.

Authors:  Chuan-Yong Guo; Xuan-Fu Xu; Jian-Ye Wu; Shu-Fang Liu
Journal:  World J Gastroenterol       Date:  2008-06-28       Impact factor: 5.742

5.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.

Authors:  Carmen J Marsit; Shichun Zheng; Kenneth Aldape; Philip W Hinds; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

6.  Molecular study of the tumour suppressor gene PTEN in gastric adenocarcinoma in Brazil.

Authors:  E M Lima; J J Araújo; M L Harada; P P Assumpção; R R Burbano; C Casartelli
Journal:  Clin Exp Med       Date:  2005-10       Impact factor: 3.984

7.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

8.  Promoter methylation and silencing of PTEN in gastric carcinoma.

Authors:  Young-Hwa Kang; Hye Seung Lee; Woo Ho Kim
Journal:  Lab Invest       Date:  2002-03       Impact factor: 5.662

9.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.

Authors:  F Perrone; A Lampis; M Orsenigo; M Di Bartolomeo; A Gevorgyan; M Losa; M Frattini; C Riva; S Andreola; E Bajetta; L Bertario; E Leo; M A Pierotti; S Pilotti
Journal:  Ann Oncol       Date:  2008-07-31       Impact factor: 32.976

10.  Pitfalls in immunohistochemical validation of tumor marker expression--exemplified in invasive cancer of the uterine cervix.

Authors:  Dan Hellberg; Tibor Tot; Ulf Stendahl
Journal:  Gynecol Oncol       Date:  2008-10-30       Impact factor: 5.482

View more
  9 in total

1.  Efficient miRNA Inhibitor with GO-PEI Nanosheets for Osteosarcoma Suppression by Targeting PTEN.

Authors:  Lingling Ou; Haiyingjie Lin; Yuwei Song; Guoqiang Tan; Xiujuan Gui; Jinyuan Li; Xiaoting Chen; Zhendong Deng; Shaoqiang Lin
Journal:  Int J Nanomedicine       Date:  2020-07-16

2.  miR-106b promotes cell invasion and metastasis via PTEN mediated EMT in ESCC.

Authors:  Jianxiang Zhang; Danjie Chen; Shuying Liang; Jun Wang; Can Liu; Caiping Nie; Zhengzheng Shan; Liuxing Wang; Qinxia Fan; Feng Wang
Journal:  Oncol Lett       Date:  2018-01-25       Impact factor: 2.967

Review 3.  PTEN and Gynecological Cancers.

Authors:  Camilla Nero; Francesca Ciccarone; Antonella Pietragalla; Giovanni Scambia
Journal:  Cancers (Basel)       Date:  2019-09-28       Impact factor: 6.639

4.  Genistein Modulates Signaling Pathways and Targets Several Epigenetic Markers in HeLa Cells.

Authors:  Madhumitha Kedhari Sundaram; Sreepoorna Unni; Pallavi Somvanshi; Tulika Bhardwaj; Raju K Mandal; Arif Hussain; Shafiul Haque
Journal:  Genes (Basel)       Date:  2019-11-21       Impact factor: 4.096

Review 5.  The Mechanisms Underlying PTEN Loss in Human Tumors Suggest Potential Therapeutic Opportunities.

Authors:  Hyeyoun Chang; Zhenying Cai; Thomas M Roberts
Journal:  Biomolecules       Date:  2019-11-07

6.  EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer.

Authors:  Song-Hee Kim; Byung-Chul Kang; Daseul Seong; Won-Hyeok Lee; Jae-Hee An; Hyoung-Uk Je; Hee-Jeong Cha; Hyo-Won Chang; Sang-Yoon Kim; Seong-Who Kim; Myung-Woul Han
Journal:  Biomolecules       Date:  2021-04-18

7.  The association of PTEN hypermethylation and breast cancer: a meta-analysis.

Authors:  Shanshan Luo; Jiansi Chen; Xianwei Mo
Journal:  Onco Targets Ther       Date:  2016-09-12       Impact factor: 4.147

8.  MicroRNA-92a promotes tumor growth and suppresses immune function through activation of MAPK/ERK signaling pathway by inhibiting PTEN in mice bearing U14 cervical cancer.

Authors:  Zeng-Hui Li; Lei Li; Lin-Ping Kang; Yan Wang
Journal:  Cancer Med       Date:  2018-05-11       Impact factor: 4.452

Review 9.  The role of HPV-induced epigenetic changes in cervical carcinogenesis (Review).

Authors:  Martha Laysla Ramos Da Silva; Beatriz Helena Dantas Rodrigues De Albuquerque; Thales Araújo De Medeiros Fernandes Allyrio; Valéria Duarte De Almeida; Ricardo Ney De Oliveira Cobucci; Fabiana Lima Bezerra; Vania Sousa Andrade; Daniel Carlos Ferreira Lanza; Jenner Christian Veríssimo De Azevedo; Josélio Maria Galvão De Araújo; José Veríssimo Fernandes
Journal:  Biomed Rep       Date:  2021-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.